Information de reference pour ce titreAccession Number: | 00043627-201004010-00014.
|
Author: | LIATSOS, GEORGE D.; MOULAKAKIS, ANTONIOS; KETIKOGLOU, IOANNIS; KLONARI, STELLA
|
Institution: | GEORGE D. LIATSOS, M.D., PH.D., is Internist; ANTONIOS MOULAKAKIS, M.D., PH.D., is Director; IOANNIS KETIKOGLOU, M.D., is Associate Director; and STELLA KLONARI, M.D., is Major in internal medicine, Department of Internal Medicine, "Hippokration" General Hospital of Athens, Athens, Greece
|
Title: | |
Source: | American Journal of Health-System Pharmacy. 67(7):531-534, April 1, 2010.
|
Abstract: | Purpose: A case of a patient who developed thrombotic thrombocytopenic purpura (TTP) after consuming a weight-loss product containing green tea is reported.
Summary: A 38-year-old, 68-kg Caucasian woman arrived at the emergency department with a one-week history of malaise, fatigue, and petechiae of the skin. She had no symptoms of infection and denied illegal drug use. Her medical history included hypothyroidism, for which she was treated with levothyroxine 150 [mu]g daily for the past four years. She reported that she had been using a green tea preparation for the two months before admission to lose body weight. The daily preparation contained 200 mg of green tea extract 5:1, equivalent to 1 g of natural green tea. On clinical examination, the patient appeared acutely ill and was afebrile, with pallor, petechiae, and purpura of the extremities. Laboratory test results at the time of admission revealed that the patient had anemia and marked thrombocytopenia. A peripheral blood smear demonstrated a feature of microangiopathic hemolytic anemia. Immunoglobulin G autoantibodies against ADAM metallopeptidase with thrombospondin type 1 motif, 13 were detected. On hospital day 3, the patient appeared confused and exhibited aphasia that was initially transient but then recurrent. Brain computerized tomography did not exhibit focal pathology. Over the next few days, her neurologic symptoms subsided and her platelet count and hematocrit value gradually increased. Plasmapheresis was performed (12 procedures). Corticosteroid treatment was also initiated. After 20 days of hospitalization, the patient was discharged.
Conclusion: A 38-year-old woman developed TTP after consuming a weight-loss product containing green tea extract for two months.
Copyright (C) 2010 American Society of Health-System Pharmacists, Inc. All rights reserved.
|
Author Keywords: | Camellia sinensis; Extracts; Levothyroxine; Plasmapheresis; Purpura; Steroids; cortico-; Toxicity.
|
References: | 1. Basu A and Lucas EA. Mechanisms and effects of green tea on cardiovascular health. Nutr Rev. 2007; 65:361-75.
2. Demeule M, Michaud-Levesque J, Annabi B, et al. Green tea catechins as novel anti-tumor and antiangiogenic compounds. Curr Med Chem Anticancer Agents. 2002; 2:441-63.
3. Sadler EJ. Von Willebrand factor, ADAMTS 13, and thrombotic thrombocytopenic purpura. Blood. 2008; 112:11-8.
4. Kaushal GP and Shah SV. The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAMS family. J Clin Invest. 2000; 105:1335-7.
5. Makimura M, Hirasawa M, Kobayashi K, et al. Inhibitory effect of tea catechins on collagenase activity. J Periodontol. 1993; 64:630-6.
6. Sazuka M, Imazawa H, Shoji Y, et al. Inhibition of collagenases from mouse lung carcinoma cells by green tea catechins and black tea theaflavins. Biosci Biotechnol Biochem. 1997; 61:1504-6.
7. Demeule M, Brossard M, Page M, et al. Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta. 2000; 1478:51-60.
8. Oneda H, Shiihara M and Inouye K. Inhibitory effects of green tea catechins on the activity of human matrix metalloproteinase 7 (matrilysin). J Biochem. 2003; 133:571-6.
9. Nakamuta M, Higashi N, Kohjima M, et al. Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. Int J Mol Med. 2005; 16:677-81.
10. Garbisa S, Sartor L, Biggin S, et al. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer. 2001; 91:822-32.
11. Cheng XW, Kuzuya M, Kanda S, et al. Epigallocatechin-3-gallate binding to MMP-2 inhibits gelatinolytic activity without influencing the attachment to extracellular matrix proteins but enhances MMP-2 binding to TIMP-2. Arch Biochem Biophys. 2003; 415:126-32.
12. Arner EC. Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol. 2002; 2:322-9.
13. Malfait AM, Liu RQ, Ijiri K, et al. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in oste-oarthritic cartilage. J Biol Chem. 2002; 277:22201-8.
14. Rodriguez Manzaneque JC, Westling J, Thai WN, et al. ADAMTS-1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun. 2002; 293:501-8.
15. Adcocks C, Collin P and Buttle DJ. Catechins from green tea (Camellia sinensis) inhibit bovine and human cartilage proteoglycan and type II collagen degradation in vitro. J Nutr. 2002; 132:341-6.
16. Vankemmelbeke MN, Jones GC, Fowles C, et al. Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. Eur J Biochem. 2003; 270:2394-403.
17. Tsai HM and Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute TTP. N Engl J Med. 1998; 339:1585-94.
18. Shelat SG, Smith JA and Zheng XL. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost. 2006; 4:1707-17.
19. Vesely SK, George JN, Lammle B, et al. ADAMTS-13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003; 102:60-8.
20. Zheng XL, Richard KM, Goodnough LT, et al. Effects of plasma exchange on plasma metalloproteinase ADAMTS-13 activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood. 2004; 103:4043-9.
21. Tsai HM, Rice L, Sarode R, et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med. 2000; 132:794-9.
22. Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007; 50:1138-43.
23. Kang WS, Lim IH, Yuk DY, et al. Anti-thrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thromb Res. 1999; 96:229-37.
24. Yang JA, Choi JH and Rhee SJ. Effects of green tea catechin on phospholipase A2 activity and antithrombus in streptozotocin diabetic rats. J Nutr Sci Vitaminol. 1999; 45:337-46.
25. Neuhaus T, Voit S, Lill G, et al. Platelet aggregation induced by the C-terminal peptide of thrombospondin-1 (4N1-1) is inhibited by epigallocatechin gallate but not by prostaglandin E1. Platelets. 2004; 15:455-7.
26. Naranjo CA, Busto U, Sellers EM, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
|
Language: | English.
|
Document Type: | Case-Report.
|
Journal Subset: | Pharmacology.
|
ISSN: | 1079-2082
|
NLM Journal Code: | CBH
|
Annotation(s) | |
|
|